Pandemic Brings an Unexpected Twist to Alum’s Protein Discovery
Susan Acton discovered ACE2 while searching for new cardiovascular drugs. Decades later, she was surprised to see it popping up in the news once COVID took hold.
University of California San Francisco
Give to UCSFSusan Acton discovered ACE2 while searching for new cardiovascular drugs. Decades later, she was surprised to see it popping up in the news once COVID took hold.
A UCSF team has engineered a tiny antibody capable of neutralizing the coronavirus.
In two preclinical models of COVID-19, plitidepsin showed a 100-fold reduction in viral replication in the lungs and demonstrated an ability to reduce lung inflammation.
UCSF and BridgeBio Pharma, Inc. today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.
Through its Office of Innovation Ventures, UC San Francisco has formalized a new strategic collaboration with Autobahn Labs, a “virtual incubator” focused on drug discovery and development, to help move scientific discoveries with therapeutic potential more quickly to market.
A group at Gladstone Institutes and UCSF has demonstrated that a large-scale and systematic genetic approach can indeed yield reliable and detailed information on the structure of protein complexes.
We asked several UCSF experts for a personal take on what will convince them that a vaccine is safe.
Every fall, Matt Jacobson relives his Parkinson’s diagnosis so future pharmacists perceive the patient behind the prescription.
AAAS Fellowship recognizes important contributions to STEM disciplines, including pioneering research, leadership within a given field, teaching and mentoring, fostering collaborations, and advancing public understanding of science.
An international team of researchers studied the three lethal coronaviruses SARS-CoV-2, SARS-CoV-1 and MERS-CoV in order to identify commonly hijacked cellular pathways and detect promising targets for broad coronavirus inhibition.
Researchers at UCSF are tackling antibiotic resistance using a different approach: redesigning existing antibiotic molecules to evade a bacterium’s resistance mechanisms